Ice Miller client TippingPoint Biosciences has announced the closing of an oversubscribed $4.5 million seed financing to advance its platform targeting disease-specific epigenetic protein interfaces. The Ice Miller team led by partners Mai Zymaris and Fabian Koenigbauer served as TippingPoint Biosciences’ intellectual property transactions counsel.

The round was led by SOSV and LKS Fund, with participation from Sazze Partners, Freeflow Ventures, StoryHouse Ventures, Sontag Innovation Fund, American Cancer Society BrightEdge, XEIA, and WeCAN. The financing will support the continued development of TippingPoint’s drug discovery platform, which is designed to recreate disease specific chromatin environments and identify highly selective biological targets.

Co-founded and led by Laura Hsieh, Ph.D., and Geeta Narlikar, Ph.D., the company is pursuing a differentiated approach to addressing challenges that have historically limited epigenetic therapies—particularly the difficulty of targeting mechanisms unique to diseased cells without affecting healthy tissue.

TippingPoint’s initial focus is Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive pediatric brainstem tumor with limited treatment options. The seed financing is expected to support proof-of-concept studies in DIPG models, while also enabling expansion of the company’s broader platform into additional disease areas driven by chromatin dysfunction.

Ice Miller’s Life Sciences practice group has extensive experience working with biotechnology companies to help them with seed-stage funding, intellectual property procurement and counseling, and licensing and strategic alliances. If you need guidance on any life sciences matter, our team is here to help.